Antineoplastic Agents, Hormonal
"Antineoplastic Agents, Hormonal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
| Descriptor ID |
D018931
|
| MeSH Number(s) |
D27.505.954.248.169
|
| Concept/Terms |
Antineoplastic Agents, Hormonal- Antineoplastic Agents, Hormonal
- Hormonal Agents, Antineoplastic
- Hormonal Antineoplastic Agents
- Hormonal Antineoplastics
- Antineoplastic Hormonal Drugs
- Drugs, Antineoplastic Hormonal
- Hormonal Drugs, Antineoplastic
- Hormonal Antineoplastic Drugs
- Antineoplastics, Hormonal
- Antineoplastic Hormonal Agents
- Agents, Antineoplastic Hormonal
- Antineoplastic Drugs, Hormonal
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Hormonal".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Hormonal".
This graph shows the total number of publications written about "Antineoplastic Agents, Hormonal" by people in this website by year, and whether "Antineoplastic Agents, Hormonal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 5 | 2 | 7 |
| 1997 | 4 | 2 | 6 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 1 | 2 |
| 2000 | 4 | 1 | 5 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 8 | 2 | 10 |
| 2004 | 6 | 5 | 11 |
| 2005 | 11 | 3 | 14 |
| 2006 | 4 | 2 | 6 |
| 2007 | 2 | 3 | 5 |
| 2008 | 1 | 0 | 1 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 0 | 2 |
| 2011 | 8 | 4 | 12 |
| 2012 | 4 | 4 | 8 |
| 2013 | 3 | 3 | 6 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 4 | 6 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 4 | 6 |
| 2018 | 2 | 4 | 6 |
| 2019 | 3 | 4 | 7 |
| 2020 | 3 | 3 | 6 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 2 | 2 |
| 2024 | 2 | 2 | 4 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Hormonal" by people in Profiles.
-
17?-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark. Breast Cancer Res. 2025 Dec 30; 28(1):28.
-
Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in Black women of low socioeconomic status. Support Care Cancer. 2025 Dec 11; 34(1):24.
-
Identification of factors associated with non-adherence to oral endocrine therapy in breast cancer patients of low socioeconomic status: a single centre retrospective study. Int J Clin Pharm. 2026 Feb; 48(1):266-273.
-
The Population-level Effect of Adjuvant Therapies on Breast Cancer Recurrence: Application of the Trend-in-Trend Design. Epidemiology. 2024 09 01; 35(5):660-666.
-
Exogenous steroid replacement in a pediatric patient with adrenocortical carcinoma receiving mitotane. Pediatr Blood Cancer. 2024 Aug; 71(8):e31072.
-
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study. J Clin Oncol. 2024 Jun 20; 42(18):2149-2160.
-
Interventions to improve oral endocrine therapy adherence in breast cancer patients. J Cancer Surviv. 2025 Jun; 19(3):930-939.
-
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.
-
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer. Sci Rep. 2022 02 04; 12(1):1972.
-
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer. Cancer Med. 2021 12; 10(23):8581-8594.